This inventor holds 1 USPTO granted patent. Top assignees: Aventis Pharma Deutschland, Gmbh, Genentech, Inc.. Active years: 2005.
Company Filing History:
1 out of 330 
1 out of 3,292 
Years Active: 2005
Title: Gerhard Brejpohl: Innovator in Pharmaceutical Chemistry
Introduction
Gerhard Brejpohl is a notable inventor based in Frankfurt, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patent. His work focuses on compounds that have potential applications in treating various diseases.
Latest Patents
Brejpohl holds a patent for the compound (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester. This invention relates to the preparation and use of this compound and its physiologically tolerable salts as pharmaceuticals. The compound is valuable for its pharmacological activity, particularly in the treatment or prophylaxis of diseases influenced by inhibiting the vitronectin receptor, such as osteoporosis.
Career Highlights
Throughout his career, Brejpohl has worked with prominent companies in the pharmaceutical industry, including Aventis Pharma Deutschland GmbH and Genentech, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Brejpohl has collaborated with notable professionals in his field, including Jean-Francois Gourvest and Thomas Gadek. These collaborations have likely enhanced his research and development efforts.
Conclusion
Gerhard Brejpohl is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable innovations. His patent reflects his commitment to advancing medical science and improving treatment options for various diseases.